Author | Melissa Johnson, MD | OncLive

Author | Melissa Johnson, MD

Articles

Dr. Melissa Johnson on Atezolizumab in Patients With NSCLC

June 10, 2016

Video

Melissa Johnson, MD, associate director, Lung Cancer Research, Sarah Cannon Research Institute, discusses the phase II BIRCH study, which is examining atezolizumab (Tecentriq) in patients with PD-L1–positive locally advanced or metastatic non–small cell lung cancer (NSCLC).

x